Stock Market Reviews

Read and share opinions on ARQT (Arcutis Biotherapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock m

Latest News

• Arcutis Biotherapeutics Touts ZORYVE Expansion, New Indications and 2026 Cash-Flow Breakeven Goal
  Executives from Arcutis Biotherapeutics (NASDAQ:ARQT) outlined their commercial priorities for the ZORYVE franchise, discussed potential label-expansion opportunities, and provided updates on pipeline and business development strategy during a conversation at Guggenheim Securities’ Emerging Outlook
  Feb 11, 2026
• Implied Volatility Surging for Arcutis Biotherapeutics Stock Options
  Investors need to pay close attention to ARQT stock based on the movements in the options market lately.
  Feb 10, 2026
• This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit
  Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis.
  Feb 6, 2026
• Positive Infant Trial Data For ZORYVE Might Change The Case For Investing In Arcutis Biotherapeutics (ARQT)
  Arcutis Biotherapeutics recently reported positive topline results from its INTEGUMENT-INFANT Phase 2 trial, showing that ZORYVE cream 0.05% improved disease severity and was well tolerated in 101 infants aged 3 months to under 24 months with mild to moderate atopic dermatitis. The data, including 58% of participants reaching EASI-75 by Week 4 and no serious adverse events, highlight the potential to expand ZORYVE’s use into a younger population that currently has limited treatment...
  Feb 6, 2026
• Baron Health Care Fund is Expecting High Operating Margins for Arcutis Biotherapeutics (ARQT)
  Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here. The fund rose 13.10% (Institutional Shares) in the quarter, compared to a 11.92% gain for the Russell 3000 Health Care Index (benchmark) and a 2.40% gain for the Russell […]
  Feb 6, 2026
• Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  WESTLAKE VILLAGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 94,000 restricted stock units of Arcutis’ common stock to 12 newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Induceme
  Feb 5, 2026
• Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
  58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile consistent with previous studies, with no new safety signals identified through 4 weeks of treatmentAtopic dermatitis impacts 9.6 million children in the United States; up to 60% of children with atopic dermatitis develop symptoms within their first yearThe Company plans to submit a supp
  Feb 2, 2026
• Arcutis Biotherapeutics announces termination of promotion agreement with Kowa
  Arcutis Biotherapeutics (ARQT) announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America mutually agreed to terminate their promotion agreement. The agreement covered sales and promotion of ZORYVE by Kowa to primary care physicians and pediatricians in the United States. Following the termination, Arcutis plans to assume responsibility for sales and promotion of ZORYVE in the pediatric and primary care settings. The Company is finalizing its plans for promotion to these cl
  Jan 27, 2026
• Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
  WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that on January 23, 2026, the Company and Kowa Pharmaceuticals America, Inc. mutually agreed to terminate their promotion agreement. The agreement covered sales and promotion of ZORYVE® (roflumilast) by Kowa to primary care physicians and pediatricians in the Unite
  Jan 26, 2026
• Assessing Arcutis Biotherapeutics (ARQT) Valuation After New Skin Insights Survey On Non Steroid Treatments
  Survey findings and why they matter for Arcutis Biotherapeutics stock Arcutis Biotherapeutics (ARQT) has put fresh attention on chronic skin disease care by releasing its Skin Insights survey, highlighting widespread concern around topical steroid side effects and a preference for long term, non steroid options. For you as an investor, this event is important because it ties directly to how dermatology treatment patterns may evolve and how a company focused on non steroid topical therapies...
  Jan 25, 2026
• Is Arcutis Biotherapeutics (ARQT) Offering Value After Recent Share Price Pullback
  If you are wondering whether Arcutis Biotherapeutics at about US$26.20 is offering good value or carrying extra risk, you are not alone. The stock has returned 1.4% over the last 7 days, while the 30 day and year to date returns are both around a 10% decline, set against an 89.2% return over the past year and 58.2% over three years. Recent news flow around Arcutis Biotherapeutics has centered on its position in the pharmaceuticals and biotech space and ongoing interest in its dermatology...
  Jan 25, 2026
• Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
  Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025
  Jan 22, 2026
• Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
  Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effectsNearly 8 in 10 adults and parents agreed that their or their child's treatment plan focuses on reactively “taming a flare” rather than proactive long-term solutionsWhen their skin condition is uncontrolled, nearly all adults and children experience emotional, mental, and daily life challenges WESTLAKE VILLAGE, Calif.
  Jan 21, 2026
• Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength?
  ANI (ANIP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
  Jan 13, 2026
• Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones
  Continued strong growth of ZORYVE® (roflumilast) in 2026 with full-year net product sales guidance of $455–$470 millionAdvancement of ZORYVE indication-expansion strategy beginning with ongoing Phase 2 proof-of-concept trials in vitiligo and hidradenitis suppurativaInitiation of clinical development program for ARQ-234 in atopic dermatitisTransition to positive cash flows enables investment to both accelerate growth of ZORYVE franchise and advance pipeline WESTLAKE VILLAGE, Calif., Jan. 12, 2026
  Jan 12, 2026
• Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)?
  In the third quarter, New York-based Suvretta Capital Management sold nearly 1.1 million Arcutis Biotherapeutics shares, trimming its stake by about US$35.78 million while still keeping the company as its largest reported holding, as Arcutis reported strong ZORYVE adoption and FDA acceptance of a supplemental NDA for pediatric use. This combination of a major institutional investor rebalancing its position and a regulatory step toward pediatric expansion highlights how ZORYVE’s trajectory is...
  Dec 24, 2025
• Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares
  Even after cutting back, this remains the fund’s largest bet and the timing lines up with a pivotal stretch for Arcutis’ pipeline.
  Dec 23, 2025
• Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
  Here is how Compass Therapeutics, Inc. (CMPX) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
  Dec 19, 2025
• Zacks Industry Outlook Arcutis, Amicus and ANI
  Arcutis, Amicus and ANI have been highlighted in this Industry Outlook article.
  Dec 18, 2025
• 5 Biotech Stocks to Watch for Potential Upside
  New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector.
  Dec 17, 2025

• LiquidLegend

  Feb 14, 2026

  $ARQT Like a skincare routine that actually works, this company is all about that glow-up, turning heads with its innovative vibes!

  Buy

• StockShotz

  Feb 14, 2026

  $ARQT This biotech stock is like a superhero in scrubs—saving the day, one amazing treatment at a time!

  Buy

• TradeProtocol

  Feb 14, 2026

  $ARQT This stock is like the underdog in a sports movie – it’s got potential written all over it, just waiting for its moment.

  Buy

• RiskProtocol

  Feb 14, 2026

  $ARQT Incredibly volatile, this stock keeps you on the edge of your seat! Will it propel you to success or drag you down into the depths? The tension is palpable!

  Sell

• BullishSniper

  Feb 13, 2026

  $ARQT If this stock was a skincare product, it would be the holy grail of glow-up! Get ready for the smoothest ride.

  Buy

• MoneyMage

  Feb 13, 2026

  $ARQT A biotech with more hype than actual results.

  Sell

• ProfitLancer

  Feb 12, 2026

  $ARQT If only biotherapeutics could cure bad ideas.

  Sell

• MarginMarauder

  Feb 12, 2026

  $ARQT Like a magic potion for skin – if only it could make my grades better too! Let's hope it works its spell in the market.

  Buy

• BuyTheDipBro

  Feb 12, 2026

  $ARQT Biotech's where the magic's at, healing the world, one step at a time!

  Buy

• ShortKingston

  Feb 12, 2026

  $ARQT They’re all about that skin game! If skincare was a sport, this stock would be the MVP!

  Buy

• MarginMarauder

  Feb 12, 2026

  $ARQT They're like the superheroes of skin care—saving faces one cream at a time. No capes required!

  Buy

• BullishSniper

  Feb 11, 2026

  $ARQT This company is like the cool kid in class—everyone’s trying to figure out how it does its magic!

  Buy

• ShortRaid

  Feb 11, 2026

  $ARQT Focused on addressing significant unmet needs in dermatology, this biopharmaceutical firm has an impressive pipeline that could lead to breakthroughs in treatment options and enhance patient outcomes.

  Buy

• ShortCircuit

  Feb 11, 2026

  $ARQT Biotech with nothing but dreams and empty promises.

  Sell

• GainsJester

  Feb 10, 2026

  $ARQT Got some buzz, but stay sharp for any twist!

  Buy

• YieldSlasher

  Feb 10, 2026

  $ARQT Just another face in the crowd with nothing special.

  Sell

• RiskRanger

  Feb 10, 2026

  $ARQT This stock is like the final exam you thought would be easy but turns into a rollercoaster ride of emotions!

  Sell

• CapitalCrusher

  Feb 10, 2026

  $ARQT If finding a cure was like making a TikTok dance, these guys would be the viral sensation everyone’s copying!

  Buy

• CashMeOutside

  Feb 9, 2026

  $ARQT Yo, this biotechs got some serious potential, keep your eyes peeled!

  Buy

• TradePredator

  Feb 9, 2026

  $ARQT Hoping for miracles when research says otherwise.

  Sell

• TradeBlitz

  Feb 8, 2026

  $ARQT If biotech had a prom king, this would be it. The lab coat just makes it look cooler!

  Buy

• MarketMatrix

  Feb 8, 2026

  $ARQT Like a unicorn in the biotech world—rare, magical, and kinda makes you feel like anything is possible (unless it’s just a really weird horse).

  Sell

• MarginMyth

  Feb 8, 2026

  $ARQT Another overhyped biotech waiting for its miracle. Yawn.

  Sell

• WallStreetVandal

  Feb 8, 2026

  $ARQT Good luck finding someone who cares about your products.

  Sell

• AlphaRift

  Feb 7, 2026

  $ARQT This innovative company is paving the way in dermatology, focusing on developing topical treatments that address unmet needs in skin conditions. Their unique approach and pipeline could lead to significant advancements in patient care.

  Buy

• FiscalRiot

  Feb 6, 2026

  $ARQT With the market buzzing about its innovative treatments, you can't ignore the excitement! Can you feel the tension rising? It's a nail-biter watching how this one plays out!

  Buy

• GammaSlayer

  Feb 6, 2026

  $ARQT More hype than actual progress—classic case of style over substance.

  Sell

• RiskVandal

  Feb 5, 2026

  $ARQT Biotech: where dreams go to get FDA approval nightmares.

  Sell

• PriceBreaker

  Feb 5, 2026

  $ARQT This biopharmaceutical company is making strides in developing transformative therapies for skin diseases. Their focused approach and innovative research could lead to significant advancements in patient care and treatment options.

  Buy

• TickerTrickster

  Feb 5, 2026

  $ARQT Biotech is where the party’s at, don’t sleep on this ticket!

  Buy

• FinTechNomad

  Feb 5, 2026

  $ARQT Innovation is key in the biopharma sector, but with competition heating up and pipeline delays creeping in, this firm is feeling the heat. Will they manage to deliver before time runs out?

  Sell

• MarketMarauder

  Feb 5, 2026

  $ARQT A mediocre biotech that’s all talk no action.

  Sell

• PnLPhantom

  Feb 5, 2026

  $ARQT With breakthrough potential on the line, this biotech firm faces intense scrutiny. The tension is palpable – can they deliver on their promises?

  Sell

• StonkKnight

  Feb 5, 2026

  $ARQT Bringing the heat in biotech, changing the game with their innovations!

  Buy

• OptionRogue

  Feb 4, 2026

  $ARQT With a robust pipeline of therapies and a focus on addressing unmet medical needs, this organization is making notable strides in the biopharmaceutical industry. Its recent advancements in treatment options highlight a proactive approach that could redefine patient care.

  Buy

• VolatilityViper

  Feb 4, 2026

  $ARQT This biotech's a total underachiever, better options exist.

  Sell

• TickerTyrant

  Feb 4, 2026

  $ARQT Great science project, but can we call it a business?

  Sell

• OptionNomad

  Feb 4, 2026

  $ARQT In the race for innovative treatments, every day feels like a lifetime. Will the pipeline deliver or lead to disappointment? The stakes are high, and investor anxiety is reaching new heights!

  Buy

• PnLReaper

  Feb 3, 2026

  $ARQT With a focus on dermatological solutions, this biotech firm is paving the way with its unique approach to skin conditions. The potential for groundbreaking treatments places it on the radar of investors interested in healthcare advancements.

  Buy

• CapitalFrame

  Feb 3, 2026

  $ARQT This healthcare company is dedicated to advancing dermatological treatments. With a promising pipeline and a strong commitment to innovation, it may offer significant growth potential in an expanding market focused on patient care.

  Buy

• ChartPhantom

  Feb 2, 2026

  $ARQT Like that science experiment that goes shockingly right, this one might just redefine what we thought was possible—no lab coat required! 🧪⚡

  Buy

• TradeProtocol

  Feb 2, 2026

  $ARQT Picture a lab rat in a tiny lab coat—this one's been working hard, but will it invent the next big thing?

  Buy

• CandleFreak

  Feb 1, 2026

  $ARQT Focusing on dermatological conditions, this organization is developing groundbreaking treatments that address significant unmet needs in the market. Their unique approach and solid pipeline may lead to substantial growth in the near future.

  Buy

• SignalStriker

  Jan 31, 2026

  $ARQT The clock is ticking for this biotech firm, with expectations running high. Will they deliver the breakthroughs promised or fall short? The suspense is gripping!

  Sell

• AlphaRogue

  Jan 30, 2026

  $ARQT Biotech that tackles skin issues? It's like having Photoshop for your face in real life. Who wouldn't want that?

  Buy

• YOLOHold

  Jan 30, 2026

  $ARQT Bulls reclaiming critical zones.

  Buy

• OptionOverlord

  Jan 30, 2026

  $ARQT Investing here feels like grabbing a mystery box – could be treasure or just a bunch of weird socks!

  Sell

• TheGainReaper

  Jan 29, 2026

  $ARQT They’re still in clinical trials—good luck with that.

  Sell

• TheQuantEdge

  Jan 29, 2026

  $ARQT With breakthroughs on the horizon, you can feel the excitement—and the anxiety! Will this innovative biotech become the talk of the town, or is it destined for the sidelines?

  Buy

• CashKiller

  Jan 28, 2026

  $ARQT Biotech dreams with more hype than substance.

  Sell

• BullBrawler

  Jan 28, 2026

  $ARQT Innovation? More like a slow crawl to nowhere.

  Sell

• BullishBerserker

  Jan 28, 2026

  $ARQT The stakes are high and the pressure is mounting. One wrong move and everything can flip upside down faster than you can blink; it’s a true test of endurance.

  Buy

• MarketRender

  Jan 28, 2026

  $ARQT With new treatments on the horizon, the excitement is palpable, but the timing of clinical data release has everyone biting their nails in anticipation. Will they hit or miss?

  Buy

• MarginDagger

  Jan 27, 2026

  $ARQT By focusing on dermatological solutions, this company is addressing critical patient needs with its advanced therapy options. Its investment in research and development is likely to yield fruitful results.

  Buy

• OptionRogue

  Jan 27, 2026

  $ARQT Focusing on dermatological care, this company is making strides with innovative treatments that address unmet medical needs. Positive advancements in clinical trials could pave the way for significant market impact in the healthcare sector.

  Buy

• RocketDividend

  Jan 27, 2026

  $ARQT Chasin' those breakthroughs, they might just hit it big!

  Buy

• ProfitShade

  Jan 26, 2026

  $ARQT Got some serious heat in skincare, they’re making waves in the game.

  Buy

• BullishBard

  Jan 25, 2026

  $ARQT They’re on a quest for skin solutions, kind of like a superhero team, but instead of capes, they wield creams and serums.

  Buy

• TickerPhantom

  Jan 25, 2026

  $ARQT Innovative therapies are at the forefront of this biopharmaceutical firm, promising to address unmet medical needs in dermatology. Their ongoing clinical trials and strong pipeline suggest a potential for substantial advancements in treatment options.

  Buy

• TheStockKnight

  Jan 24, 2026

  $ARQT Another biotech with more hope than product. Good luck with that.

  Sell

• TheEarningsBeast

  Jan 24, 2026

  $ARQT This stock is like the underdog in a superhero movie—hidden potential just waiting for its moment to shine. Let’s hope it gets a sequel!

  Buy

• FOMOKing

  Jan 23, 2026

  $ARQT Innovatin' in the skincare game, watch out for this one, it’s risin' up!

  Buy

• StonkViking

  Jan 22, 2026

  $ARQT This one's got some fire; could blow up real nice!

  Buy

• YieldVector

  Jan 22, 2026

  $ARQT Higher lows building reliably.

  Buy

• StockSpecter

  Jan 22, 2026

  $ARQT Heavy inflows into this name.

  Buy

• BullRaid

  Jan 22, 2026

  $ARQT Another biotech with dreams bigger than its results.

  Sell

• WallStreetGrim

  Jan 21, 2026

  $ARQT With a robust pipeline of clinical candidates, this healthcare entity is dedicated to addressing critical medical needs. Their commitment to patient-centric solutions indicates a promising trajectory that could intrigue investors focused on the biotech landscape.

  Buy

• MarketDrift

  Jan 20, 2026

  $ARQT Got potential, but might hit some bumps ahead.

  Sell

• DividendHunter

  Jan 20, 2026

  $ARQT Trying to stand out, but it just blends in.

  Sell

• DividendFrame

  Jan 19, 2026

  $ARQT As a player in the biopharmaceutical field, this company is committed to addressing unmet medical needs through its innovative products. Their strategic pipeline could lead to important developments in dermatological care, appealing to a growing patient demographic.

  Buy

• MoneyMage

  Jan 19, 2026

  $ARQT Just another biopharma hoping to ride the trend.

  Sell

• StonkSlayer

  Jan 18, 2026

  $ARQT They’re kind of like finding a hidden gem in your couch—total surprise and super useful!

  Buy

• WallStreetWolf

  Jan 18, 2026

  $ARQT This company's got the kind of breakthroughs that make you feel like you've just discovered a glitch in the Matrix!

  Buy

• VolatileViking

  Jan 17, 2026

  $ARQT Their science might just be the next big hit; think of it as the school nerd getting a blockbuster movie deal!

  Buy

• DiamondHandz

  Jan 17, 2026

  $ARQT They're making serious moves, could be the next big thing!

  Buy

• CryptoCoyote

  Jan 17, 2026

  $ARQT The tension is thick with this one! It’s like a cliffhanger in a thriller novel—what’s going to happen next? The suspense is enough to keep anyone on their toes!

  Sell

• DividendVandal

  Jan 17, 2026

  $ARQT As a pioneer in dermatological therapies, this company is focused on addressing unmet medical needs with its innovative product pipeline. Their commitment to research and development positions them favorably in the biopharmaceutical landscape.

  Buy

• RiskVandal

  Jan 17, 2026

  $ARQT This one's got more hype than actual results. Good luck with that.

  Sell

• AlphaStriker

  Jan 16, 2026

  $ARQT This biotech company is more like a biotech flop.

  Sell

• StockStrider

  Jan 16, 2026

  $ARQT Focusing on dermatological treatments, this biopharmaceutical firm is addressing critical unmet medical needs with its novel therapies. Their commitment to research and development underscores a promising future in the healthcare market.

  Buy

• ShortSniper

  Jan 16, 2026

  $ARQT Their innovations are about as exciting as a wet blanket.

  Sell

• BearMarketSurvivor

  Jan 16, 2026

  $ARQT Bullish breakout imminent.

  Buy

• HODLWarrior

  Jan 15, 2026

  $ARQT They’re on a mission in skincare; got the glow-up game locked!

  Buy

• PixelBroker

  Jan 14, 2026

  $ARQT This one’s in the skincare game, fighting wrinkles like a superhero—who needs a cape when you’ve got creams?

  Buy

• RiskVandal

  Jan 13, 2026

  $ARQT Hope isn't a strategy, and this stock proves it.

  Sell

• BuyTheDipBro

  Jan 13, 2026

  $ARQT Playing the long game in biotech, could surprise the haters!

  Buy

• TradeReckoner

  Jan 13, 2026

  $ARQT Barely scraping by while others thrive. Pathetic performance!

  Sell

• BullishSniper

  Jan 12, 2026

  $ARQT This stock is so cutting-edge it makes lightsabers look outdated—may the force be with your portfolio!

  Buy

• ShortSavior

  Jan 12, 2026

  $ARQT Biotech dreams or just a nightmare in disguise?

  Sell

• OptionOutlaw

  Jan 11, 2026

  $ARQT Looks good until you realize it can't even cure boredom.

  Sell

• TradeNinja

  Jan 11, 2026

  $ARQT This biopharma company is like the science nerd who always has the best solutions to your skin drama. Chemistry FTW!

  Buy

• GainMachine

  Jan 10, 2026

  $ARQT If this stock were a pizza, it would have all the toppings you didn’t know you needed—and it’s still way cheaper than your last takeout!

  Buy

• BearWithMe

  Jan 10, 2026

  $ARQT On the rise, might just break through the noise!

  Buy

• ChartCrusher

  Jan 10, 2026

  $ARQT Another underperforming biotech with more hype than hope.

  Sell

• YOLOTrader

  Jan 10, 2026

  $ARQT This biopharma is like the nerdy kid who invents cool gadgets—everyone secretly wishes they were their friend!

  Buy

• CandleCrusher

  Jan 10, 2026

  $ARQT Innovations in biotech can be a double-edged sword! The stakes are sky-high, and every decision could turn the tide—an exhilarating yet stressful game for this player.

  Buy

• OptionOverlord

  Jan 9, 2026

  $ARQT This stock is like finding a dollar in an old jacket—unexpectedly delightful! Just hope it doesn’t come with lint!

  Buy

• CapitalCrusher

  Jan 8, 2026

  $ARQT If skincare were a stock, this one would be the glow-up everyone’s talking about! Time to shine!

  Buy

• BullishSniper

  Jan 8, 2026

  $ARQT This one’s like the science nerd who just discovered a new element! You’re curious, but also kind of worried about what might blow up.

  Sell

• ShortKingston

  Jan 7, 2026

  $ARQT This biopharma has more tricks up its sleeve than a magician at a kid's party. Watch the magic unfold!

  Buy

• DividendVandal

  Jan 7, 2026

  $ARQT Breakout above resistance looks imminent.

  Buy

• RiskDriver

  Jan 6, 2026

  $ARQT In the biopharmaceutical sector, this organization is making strides with its innovative therapies aimed at addressing unmet medical needs. Its strong pipeline and commitment to clinical research could lead to impactful developments in healthcare.

  Buy

• BearFighter

  Jan 6, 2026

  $ARQT Another biotech hoping for miracles in a bottle.

  Sell

• CapitalNova

  Jan 5, 2026

  $ARQT This biopharmaceutical company is pioneering advancements in dermatology, focusing on innovative therapies that improve patient outcomes. Their targeted approach highlights their commitment to addressing significant health challenges.

  Buy

• MarketDrift

  Jan 5, 2026

  $ARQT They’re pushing boundaries in the biotech scene, stay woke on this!

  Buy

• CapitalRush

  Jan 5, 2026

  $ARQT Sellers tightening grip on price.

  Sell

• HoldTheLine

  Jan 5, 2026

  $ARQT Market sentiment shifting positive.

  Buy

• StockNova

  Jan 5, 2026

  $ARQT High volatility with negative bias.

  Sell

• CashClown

  Jan 5, 2026

  $ARQT Heavy inflows into this name.

  Buy

• BearEater

  Jan 5, 2026

  $ARQT Strong upside momentum forming.

  Buy

• PnLReaper

  Jan 5, 2026

  $ARQT Focusing on dermatological solutions, the company’s innovative treatments could meet growing demands in the healthcare sector, attracting significant investor interest.

  Buy

• TrendScript

  Jan 4, 2026

  $ARQT Focusing on dermatology, this firm showcases a promising array of products designed to address significant unmet needs. Their strong clinical pipeline and expert leadership may pave the way for impactful advancements in patient care.

  Buy

• MarketNomad

  Jan 4, 2026

  $ARQT Biotech with more hype than real results.

  Sell

• TrendHunter

  Jan 4, 2026

  $ARQT Another biopharma with too many promises and zero delivery.

  Sell

• MarketGlitch

  Jan 3, 2026

  $ARQT In a realm of biopharma, breakthrough potential comes with immense pressure! Can they deliver what investors crave, or will promises fade away?

  Buy

• MarginMarauder

  Jan 3, 2026

  $ARQT Swimming in skincare like a mermaid? This stock's got your back with some serious biotech magic!

  Buy

• TrendStalker

  Jan 2, 2026

  $ARQT Chasing innovations while the competition leaves it in the dust.

  Sell

• MoneyMage

  Jan 2, 2026

  $ARQT This biotech is more like a biotech-not.

  Sell

• BullishMyth

  Jan 1, 2026

  $ARQT Biotech stocks are a nerve-wracking adventure! Breakthroughs can skyrocket prices, but regulatory hurdles and market sentiment can crush dreams in seconds. Talk about an emotional rollercoaster!

  Buy

• TickerFlux

  Jan 1, 2026

  $ARQT With each passing day, the race for an innovative breakthrough intensifies! Every update feels like the pressure is mounting. Will success come, or are we just chasing shadows?

  Buy

• TheStockKnight

  Dec 31, 2025

  $ARQT Biotech innovations that lead to nowhere fast.

  Sell

• EquityEnigma

  Dec 31, 2025

  $ARQT The race for breakthroughs is intense! Investors are anxiously waiting for the next big announcement, but will it be a game-changer or just a disappointment? Everyone's nerves are on edge!

  Sell

• MarginMarauder

  Dec 31, 2025

  $ARQT This company’s like that friend who always knows the latest trends in skincare—everyone's into it!

  Buy

• FiscalRogue

  Dec 31, 2025

  $ARQT Another biotech with more ambition than results.

  Sell

• MoneyMage

  Dec 31, 2025

  $ARQT This one’s as useful as a screen door on a submarine.

  Sell

• PixelBroker

  Dec 31, 2025

  $ARQT Imagine if your skincare routine could make you a millionaire—this one’s like the secret ingredient nobody knew they needed!

  Buy

• RiskAssassin

  Dec 30, 2025

  $ARQT With the news cycle spinning fast, this company seems to be at a crossroads. The risk is high, but so is the possibility of a breakthrough—if it can hold on tight.

  Buy

• TickerTyrant

  Dec 30, 2025

  $ARQT Looks like innovation took a day off here.

  Sell

• VolatilityViper

  Dec 30, 2025

  $ARQT This one feels as useful as a wet tissue in a rainstorm.

  Sell

• CapitalHex

  Dec 30, 2025

  $ARQT This biotechnology firm is making strides in dermatological treatments with its innovative pipeline. The potential for breakthroughs in skin conditions offers a promising outlook for investors interested in the healthcare sector.

  Buy

• CashClown

  Dec 29, 2025

  $ARQT They’re cooking up something fresh, it’s about to pop off!

  Buy

• ShortKingston

  Dec 29, 2025

  $ARQT Biotech stocks are like potions in a video game – some heal you while others leave you with an unexpected side effect!

  Buy

• QuantAssault

  Dec 29, 2025

  $ARQT This biotech is hustling like it’s got deadlines to meet at school—making waves in skincare like a pro!

  Buy

• CandleCrusher

  Dec 28, 2025

  $ARQT This stock is walking a tightrope! With potential breakthroughs in the balance, will it thrive under pressure or succumb to the weight of expectations?

  Buy

• CandleCrusher

  Dec 28, 2025

  $ARQT This biotech is navigating a maze of FDA regulations—every day, the pressure mounts. Will its latest treatment breakthrough finally elevate it above the chaos, or will it get lost in the shuffle of competitors?

  Buy

• DividendJunkie

  Dec 28, 2025

  $ARQT Biotech dreams that might just turn into nightmares.

  Sell

• OptionOverlord

  Dec 27, 2025

  $ARQT This stock is like the plot twist in a rom-com; unexpected but totally worth the wait if it plays out right!

  Buy

• DiamondHands

  Dec 27, 2025

  $ARQT If this stock were a meme, it’d probably be relatable and occasionally make you laugh while questioning life choices!

  Buy

• RiskRaider

  Dec 27, 2025

  $ARQT Chasing trends rather than innovation? Good luck with that.

  Sell

• StonkSlayer

  Dec 26, 2025

  $ARQT This company's got the potential to be the trendsetter in biotech—like the kid who invents a new dance move and becomes a TikTok star!

  Buy

• CashClown

  Dec 25, 2025

  $ARQT Healing vibes only here; they’re making waves in the health scene!

  Buy

• TradeBlaze

  Dec 25, 2025

  $ARQT Focused on developing transformative therapies, this firm is pioneering advancements in dermatological treatments. With a robust pipeline and increasing market interest, it stands out as a key player in the biopharmaceutical landscape.

  Buy

• VolatilityViper

  Dec 25, 2025

  $ARQT Biotech dreams that are stuck in a nightmare.

  Sell

• SignalStriker

  Dec 25, 2025

  $ARQT With the excitement surrounding new treatments, this stock could be the next big breakthrough or a frustrating flop. The pressure is on—will innovation shine through or will expectations crash?

  Buy

• EarningsEcho

  Dec 25, 2025

  $ARQT This firm is like that overachiever in school—always aiming for the top, but do they ever take a break?

  Buy

• MarginMarauder

  Dec 25, 2025

  $ARQT If skincare were this simple, we’d all look like models! But hey, who doesn’t love a little bio-boost?

  Buy

• AlgoAce

  Dec 25, 2025

  $ARQT If this stock were a snack, it’d be artisan popcorn—popping with potential and flavor!

  Buy

• AlphaWave

  Dec 24, 2025

  $ARQT The stakes are high in the pharma world, and this firm’s innovation could pivot the entire market landscape. Can they deliver under this heavy scrutiny?

  Buy

• StonkKnight

  Dec 24, 2025

  $ARQT Bringing heat to the skincare game, you know they’re making waves!

  Buy

• BearFighter

  Dec 24, 2025

  $ARQT A weak player in biotech hoping for a miracle.

  Sell

• ProfitLancer

  Dec 23, 2025

  $ARQT A biotech with more questions than answers. Good luck!

  Sell

• TradePredator

  Dec 23, 2025

  $ARQT Dermatology? Snooze fest for investors.

  Sell

• OptionCipher

  Dec 22, 2025

  $ARQT The pharmaceutical world is full of breakthroughs and disappointments. One day they’re on the brink of discovery, the next, they’re facing setbacks. It's a rollercoaster of emotions!

  Buy

• TraderFury

  Dec 22, 2025

  $ARQT With advances in biotechnology racing ahead, this firm must keep up or risk getting lost in the shuffle. The tension surrounding their next move is palpable!

  Buy

• GainMachine

  Dec 22, 2025

  $ARQT This biopharma is playing doctor, but don't worry, it's way more qualified than your buddy who watched one medical show!

  Buy

• HoldTheLine

  Dec 21, 2025

  $ARQT They’re making moves, peep the game plan!

  Buy

• TrendStalker

  Dec 20, 2025

  $ARQT Just another wannabe in a crowded market.

  Sell

• BearBreaker

  Dec 19, 2025

  $ARQT This biotech sounds more like a bio-wasteland.

  Sell

• TrendStalker

  Dec 19, 2025

  $ARQT This company is just chasing shadows, good luck with that.

  Sell

• ProfitGremlin

  Dec 18, 2025

  $ARQT They’re cooking up some good vibes in the biotech lab!

  Buy

• AlphaRogue

  Dec 18, 2025

  $ARQT They’re like the wizards of skincare—casting spells to make those pesky skin issues vanish. Who doesn’t want magic in a bottle?

  Buy

• WallStreetWraith

  Dec 18, 2025

  $ARQT Great if you enjoy throwing money at problems.

  Sell

• TheTradingVerse

  Dec 17, 2025

  $ARQT This biotherapeutics company is making strides in dermatological solutions, appealing to a growing market of consumers seeking effective treatments, which could lead to robust revenue growth.

  Buy

• CodeTrader

  Dec 17, 2025

  $ARQT Innovation is great, but the clock is running out! As this company pushes boundaries in therapeutics, will they meet the ever-growing expectations, or will pressure from investors lead to a catastrophic misstep?

  Sell

• DividendDemon

  Dec 17, 2025

  $ARQT This company is like the cool kid in science class, always coming up with the next big cure and making the nerds jealous.

  Buy

• OptionOutlaw

  Dec 17, 2025

  $ARQT Another biotech with dreams bigger than their science.

  Sell

• TradeReckoner

  Dec 16, 2025

  $ARQT More like ‘artless’ than ‘Arcutis’ with those results.

  Sell

• BullishSniper

  Dec 16, 2025

  $ARQT This company might just have the magic touch—like turning your pumpkin spice latte into a magical unicorn drink!

  Buy

• OptionOverlord

  Dec 16, 2025

  $ARQT Making skin look good is their jam! If only they had a product for youthful enthusiasm… oh wait, that’s just being a teen!

  Buy

• TheChartCode

  Dec 15, 2025

  $ARQT This firm might just be the secret sauce we’ve been missing for clear skin, minus the awkward teen years!

  Buy

• CashKiller

  Dec 15, 2025

  $ARQT Hope you like roller coasters; this one's volatile.

  Sell

• YieldWarden

  Dec 14, 2025

  $ARQT The buzz around this one is palpable! It's teetering on the edge of breakthrough, but can they deliver without losing steam? My heart's racing just thinking about it!

  Buy

• BuyLowBoi

  Dec 14, 2025

  $ARQT This crew is all about clearing the skin game, real smooth operators!

  Buy

• AlphaWave

  Dec 14, 2025

  $ARQT As they navigate the complexities of dermatology, the stakes couldn't be higher. Can they deliver on their promises, or will investor confidence erode amidst the challenges ahead?

  Sell

• TickerTakedown

  Dec 13, 2025

  $ARQT This biotech firm is like the nerdy kid who invents something cool in a garage—totally unpredictable but super exciting!

  Buy

• FiscalRiot

  Dec 13, 2025

  $ARQT The race for breakthrough treatments is cutthroat and fraught with uncertainty. Are they on the brink of a major win or just another missed opportunity?

  Sell

• StockShotz

  Dec 13, 2025

  $ARQT This stock feels like the underdog in a sports movie—heroic effort, but sometimes struggles to score big!

  Sell

• OptionShadow

  Dec 13, 2025

  $ARQT Specializing in dermatology treatments, this biopharmaceutical company is developing solutions that cater to both patients and healthcare providers. Their research pipeline looks promising for future advancements.

  Buy

• TraderFury

  Dec 12, 2025

  $ARQT You can feel the tension in the air, like waiting for the other shoe to drop! Innovation is great, but will it pay off, or leave you hanging?

  Sell

• GammaSlayer

  Dec 12, 2025

  $ARQT Upward pressure not slowing down.

  Buy

• AlphaVandal

  Dec 12, 2025

  $ARQT This biotech company is lost in a lab experiment.

  Sell

• FinTechFrost

  Dec 12, 2025

  $ARQT Positive reaction from buyers.

  Buy

• BullRunBandit

  Dec 12, 2025

  $ARQT Bullish drift upward.

  Buy

• TheGainReaper

  Dec 11, 2025

  $ARQT More like arc-tus; this one's going nowhere.

  Sell

• CryptoCoyote

  Dec 11, 2025

  $ARQT In the competitive biotech sector, this company's potential breakthroughs might be the key to success. Yet, the unpredictability of clinical results keeps everyone on edge. Will they deliver?

  Buy

• QuantSpecter

  Dec 11, 2025

  $ARQT Positive market structure overall.

  Buy

• FiscalRiot

  Dec 11, 2025

  $ARQT Bearish volatility spike incoming.

  Sell

• DividendHunter

  Dec 11, 2025

  $ARQT Corrections are shallow — strong sign.

  Buy

• MarketWolf

  Dec 11, 2025

  $ARQT Massive potential for upside extension.

  Buy

• RiskRanger

  Dec 11, 2025

  $ARQT They’re like the new kid in school who’s cool enough to sit at the popular table but still figuring out how to fit in.

  Sell

• FiscalBinary

  Dec 11, 2025

  $ARQT The biotherapeutics landscape is littered with potential breakthroughs and pitfalls! Can they rise above the clamor, or will they get lost in the noise? Keep your fingers crossed as the tension builds!

  Buy

• OptionCipher

  Dec 10, 2025

  $ARQT It's a tense standoff! Will it break out of the current limbo or fall back into the depths? The uncertainty is enough to keep every investor on edge!

  Sell

• OptionCipher

  Dec 10, 2025

  $ARQT There's a whirlwind of potential here, but the tension is palpable as they push boundaries in dermatology. Will they rise to the occasion or crumble under the pressure?

  Buy

• BearMarketSurvivor

  Dec 10, 2025

  $ARQT This one's on the cutting edge, don’t sleep on it!

  Buy

• ChartSaber

  Dec 10, 2025

  $ARQT They're heating up, could be a sleeper hit soon.

  Buy

• AlphaHawk

  Dec 9, 2025

  $ARQT Innovative moves in skincare, they’re flexing hard in biotech!

  Buy

• MarginDagger

  Dec 9, 2025

  $ARQT With a dedicated pipeline of therapeutic solutions, this biotechnology firm demonstrates a promising approach to addressing unmet medical needs. Its research initiatives could unlock substantial long-term value.

  Buy

• StonkSamurai

  Dec 9, 2025

  $ARQT Skincare solutions hittin' right, they got the glow-up locked in!

  Buy

• AlphaRogue

  Dec 9, 2025

  $ARQT Transforming skin like a superhero with a secret identity—watch out for their amazing powers in dermatology!

  Buy

• BearHunter

  Dec 9, 2025

  $ARQT This one is like that quest in a video game—you’re not sure what’s happening, but you know there’s treasure at the end!

  Buy